US 12,214,029 B2
Polysaccharide and uses thereof
Michael T. Kowarik, Zurich (CH); Michael L. Wetter, Zurich (CH); Stefan J. Kemmler, Zurich (CH); Micha A. Häuptle, Zurich (CH); Veronica Gambillara, Meilen (CH); and Manuela Mally, Watt (CH)
Assigned to GLAXOSMITHKLINE BIOLOGICALS S.A., Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS S.A., Rixensart (BE)
Filed on Apr. 24, 2023, as Appl. No. 18/305,948.
Application 15/643,788 is a division of application No. 14/628,844, filed on Feb. 23, 2015, granted, now 9,700,612, issued on Jul. 11, 2017.
Application 18/305,948 is a continuation of application No. 17/165,333, filed on Feb. 2, 2021, granted, now 11,738,076.
Application 17/165,333 is a continuation of application No. 16/599,900, filed on Oct. 11, 2019, granted, now 10,940,192, issued on Mar. 9, 2021.
Application 16/599,900 is a continuation of application No. 15/643,788, filed on Jul. 7, 2017, granted, now 10,441,647, issued on Oct. 15, 2019.
Claims priority of provisional application 61/943,710, filed on Feb. 24, 2014.
Prior Publication US 2023/0364214 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/108 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 47/64 (2017.01); C07K 14/21 (2006.01); C07K 14/245 (2006.01); C08B 37/00 (2006.01)
CPC A61K 39/0258 (2013.01) [A61K 39/02 (2013.01); A61K 47/646 (2017.08); C07K 14/21 (2013.01); C08B 37/0063 (2013.01); C08B 37/0066 (2013.01); A61K 2039/55583 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6087 (2013.01); A61K 2039/70 (2013.01); C07K 14/245 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A pharmaceutical composition comprising a glycoconjugate of an E. coli O25B antigen covalently coupled to a carrier protein, wherein the E. coli O25B antigen comprises the structure of Formula O25B′:

OG Complex Work Unit Chemistry
wherein n is an integer of 1 to 30; and a pharmaceutically acceptable carrier.